Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 43
1946 190
1947 144
1948 130
1949 127
1950 1
1951 171
1952 366
1953 353
1954 350
1955 298
1956 224
1957 264
1958 247
1959 92
1960 4
1961 15
1962 18
1963 95
1964 166
1965 849
1966 2093
1967 3738
1968 5470
1969 7221
1970 8319
1971 9616
1972 11324
1973 12664
1974 13584
1975 11155
1976 9702
1977 10896
1978 11550
1979 12562
1980 11329
1981 11189
1982 13391
1983 16049
1984 14935
1985 15501
1986 15969
1987 17047
1988 19620
1989 21857
1990 23774
1991 23588
1992 23731
1993 23502
1994 24669
1995 25215
1996 25219
1997 26476
1998 27147
1999 26536
2000 29435
2001 31253
2002 33927
2003 37803
2004 40062
2005 42890
2006 45261
2007 46733
2008 49765
2009 51908
2010 54968
2011 60109
2012 63658
2013 65410
2014 65345
2015 67646
2016 65541
2017 65489
2018 63726
2019 63660
2020 55691
2021 38007
2022 9895
2023 8468
2024 53998
2025 61497
2026 429

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,668,558 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for pd ad
Search for PhD AD instead (1 results)
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS, Ou YC, Trotman J, Opat S. Tam CS, et al. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20. Expert Rev Clin Pharmacol. 2021. PMID: 34491123 Free article. Review.
Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, for the adverse effects seen with other BTK inhibitors.Areas covered: This drug profile covers zanubrutinib clinical pharmacology and …
Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, …
Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Saraiva C, et al. J Control Release. 2016 Aug 10;235:34-47. doi: 10.1016/j.jconrel.2016.05.044. Epub 2016 May 18. J Control Release. 2016. PMID: 27208862 Free article. Review.
In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged and more permeable BBB can pose serious challenges to drug delivery into the brain. ...In this review, we will discuss BB …
In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. Howev …
Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation.
Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Eleveld DJ, et al. Br J Anaesth. 2018 May;120(5):942-959. doi: 10.1016/j.bja.2018.01.018. Epub 2018 Mar 12. Br J Anaesth. 2018. PMID: 29661412 Free article.
BACKGROUND: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infusion (TCI) systems to determine the optimal drug administration to achieve a desired target concentration in a central or effect-site compartment. ...CONCLUSIONS: We d …
BACKGROUND: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infusion (TCI) systems to determine th …
Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review.
Mincic AM, Antal M, Filip L, Miere D. Mincic AM, et al. Clin Nutr. 2024 Jul;43(7):1832-1849. doi: 10.1016/j.clnu.2024.05.036. Epub 2024 May 31. Clin Nutr. 2024. PMID: 38878554 Free article.
This review examines the effects of microbiota modulation through administration of probiotics, prebiotics, symbiotics, or prebiotics' metabolites (postbiotics) in patients with ND like multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD …
This review examines the effects of microbiota modulation through administration of probiotics, prebiotics, symbiotics, or prebiotics …
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases.
Moosavi SG, Rahiman N, Jaafari MR, Arabi L. Moosavi SG, et al. J Control Release. 2025 May 10;381:113641. doi: 10.1016/j.jconrel.2025.113641. Epub 2025 Mar 20. J Control Release. 2025. PMID: 40120689 Review.
This review discusses the pathophysiological mechanisms of neurological disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), Huntington's disease (HD), ischemic stroke, spinal cord injury, and Friedreich's ataxia. ...
This review discusses the pathophysiological mechanisms of neurological disorders, including Parkinson's disease (PD), Alzheimer's di …
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H, Nakagawa K. Hayashi H, et al. Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23. Int J Clin Oncol. 2020. PMID: 31549270 Review.
Preclinical studies have suggested that the combination of PD-1 or PD-L1 inhibitors with either cytotoxic chemotherapy or antibodies to CTLA-4 is a promising treatment strategy for advanced cancer. ...The identification of patients likely to achieve a sufficient ben …
Preclinical studies have suggested that the combination of PD-1 or PD-L1 inhibitors with either cytotoxic chemotherapy or anti …
Coffee, antioxidants, and brain inflammation.
Rai SP, Ansari AH, Singh D, Singh S. Rai SP, et al. Prog Brain Res. 2024;289:123-150. doi: 10.1016/bs.pbr.2024.06.005. Epub 2024 Jul 3. Prog Brain Res. 2024. PMID: 39168577 Review.
It is postulated that coffee consumption reduces neuroinflammation, which is intimately linked to the onset of neurodegenerative disorders like Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Hunt …
It is postulated that coffee consumption reduces neuroinflammation, which is intimately linked to the onset of neurodegenerative disorders l …
Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer.
Xu J, Tian Y, Zhao B, Hu D, Wu S, Ma J, Yang L. Xu J, et al. Mol Biomed. 2024 Sep 10;5(1):37. doi: 10.1186/s43556-024-00200-3. Mol Biomed. 2024. PMID: 39251538 Free PMC article.
We showed that combined therapy with an adenovirus encoding human endostatin, named Ad-E, and PD-1 blockade dramatically abrogated MC38 tumor growth. The structure of intestinal microbes in mice was changed after combination treatment. ...Our results suggested that …
We showed that combined therapy with an adenovirus encoding human endostatin, named Ad-E, and PD-1 blockade dramatically abrog …
PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.
Mu RJ, Liu TL, Liu XD, Liu L. Mu RJ, et al. Acta Pharmacol Sin. 2024 Aug;45(8):1752-1764. doi: 10.1038/s41401-024-01255-2. Epub 2024 Apr 3. Acta Pharmacol Sin. 2024. PMID: 38570601 Free PMC article.
The pharmacokinetics of morphine and M6G following oral or intravenous administration were simulated, and the PBPK-PD model was validated using clinical observations. ...The contribution of morphine to CNS effects following intravenous or oral administration …
The pharmacokinetics of morphine and M6G following oral or intravenous administration were simulated, and the PBPK-PD model wa …
The safety of anti PD-1 therapeutics for the treatment of melanoma.
Ramelyte E, Schindler SA, Dummer R. Ramelyte E, et al. Expert Opin Drug Saf. 2017 Jan;16(1):41-53. doi: 10.1080/14740338.2016.1248402. Epub 2016 Oct 24. Expert Opin Drug Saf. 2017. PMID: 27737598 Review.
The two FDA-approved checkpoint inhibitors against PD-1 (nivolumab and pembrolizumab) have been shown to significantly improve patient survival while being less toxic than previous treatment options. ...Expert opinion: Even though anti-PD-1 therapies are better tole …
The two FDA-approved checkpoint inhibitors against PD-1 (nivolumab and pembrolizumab) have been shown to significantly improve patien …
1,668,558 results
You have reached the last available page of results. Please see the User Guide for more information.